Journal of Gastroenterology and Hepatology最新文献

{"title":"The Need for Mature Overall Survival Data Before Routine Adoption of TACE-Immunotherapy Combinations in HCC.","authors":"YaoYao Dai, Yeyun Lu, WenQiang Xie","doi":"10.1111/jgh.70663","DOIUrl":"10.1111/jgh.70663","url":null,"abstract":"","PeriodicalId":15877,"journal":{"name":"Journal of Gastroenterology and Hepatology","volume":" ","pages":"3236-3237"},"PeriodicalIF":3.5,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148764915","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Accounting for Endoscopy Capacity When Linking Barrett's Esophagus Identification and Surveillance.","authors":"Yuqi He, Jianhong Zhang, Sheng Li","doi":"10.1111/jgh.70664","DOIUrl":"10.1111/jgh.70664","url":null,"abstract":"","PeriodicalId":15877,"journal":{"name":"Journal of Gastroenterology and Hepatology","volume":" ","pages":"3238-3239"},"PeriodicalIF":3.5,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148813161","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Industry Funding, Voting Conflicts, and a Single Delphi Round: Concerns About the Southeast Asia PPI Rationalization Consensus.","authors":"Prathina, Barkha, Muhammad Aslam","doi":"10.1111/jgh.70700","DOIUrl":"10.1111/jgh.70700","url":null,"abstract":"","PeriodicalId":15877,"journal":{"name":"Journal of Gastroenterology and Hepatology","volume":" ","pages":"3287-3288"},"PeriodicalIF":3.5,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148829258","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Systemic Therapy for Advanced Gastroesophageal Cancer in 2026: Current Standard of Care and Emerging Therapeutic Strategies","authors":"Glenn Jia Hoe Chua,&nbsp;Chiew Woon Lim,&nbsp;Kennedy Yao Yi Ng,&nbsp;Justina Yick Ching Lam,&nbsp;Matthew Chau Hsien Ng,&nbsp;Evelyn Yi Ting Wong","doi":"10.1111/jgh.70678","DOIUrl":"10.1111/jgh.70678","url":null,"abstract":"<p>\u0000 \u0000 <figure>\u0000 <div><picture>\u0000 <source></source></picture><p></p>\u0000 </div>\u0000 </figure></p>","PeriodicalId":15877,"journal":{"name":"Journal of Gastroenterology and Hepatology","volume":"41 10","pages":"3089-3100"},"PeriodicalIF":3.5,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jgh.70678","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148793966","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gaps in the Cascade of Care Contribute to Poor Liver Cancer Outcomes Among People Living With Hepatitis B: A Multicenter Observational Cohort Study","authors":"Dina Moussa,&nbsp;Joan Ericka Flores,&nbsp;Michael Macisaac,&nbsp;Jack Wallace,&nbsp;Joseph Doyle,&nbsp;Marno Ryan,&nbsp;Thai Hong,&nbsp;Brett Knowles,&nbsp;Adrian Fox,&nbsp;Ashu Jhamb,&nbsp;Tom Sutherland,&nbsp;Stuart Roberts,&nbsp;William Kemp,&nbsp;Ammar Majeed,&nbsp;Marie Sinclair,&nbsp;Rohit Sawhney,&nbsp;Stephen Bloom,&nbsp;Amanda Nicoll,&nbsp;Zina Valaydon,&nbsp;Gauri Mishra,&nbsp;Sid Sood,&nbsp;Diana Lewis,&nbsp;A. Thompson,&nbsp;J. Howell","doi":"10.1111/jgh.70680","DOIUrl":"10.1111/jgh.70680","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Chronic hepatitis B virus (HBV) remains a major cause of hepatocellular carcinoma (HCC) in Australia, despite the availability of effective, subsidized antiviral therapy. We aimed to describe the clinical characteristics, HBV care cascade, and outcomes among people with HBV-related HCC in Victoria, Australia.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We conducted a multicenter cohort study of all incident HCC cases across eight tertiary health networks in Victoria, Australia. Cases were identified retrospectively (January 1, 2018 to December 31, 2019) and prospectively (January 1, 2020 to October 17, 2022). The primary outcome was the proportion of incident HCC attributable to HBV. Secondary outcomes included uptake of guideline-based antiviral therapy and surveillance and overall survival from HCC diagnosis. Multivariable logistic regression was used to identify factors associated with treatment and surveillance uptake.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Among 1203 incident HCC cases, 219 (18.2%) were HBV related. Most patients were male (89%) and of Asian ethnicity (60%). While 61% were aged 56–75 years, 25% were 36–55 years. Cirrhosis was present in 141 (64%), although 57 (26%) were newly diagnosed with cirrhosis at HCC presentation. The 121 (60%) patients were eligible for antiviral therapy. Linkage to specialist care was associated with treatment uptake (adjusted OR 8.4, 95% CI 4.3–16.1; <i>p</i> &lt; 0.001). Surveillance enrolment at diagnosis was higher among HBV-related HCC compared with non-HBV HCC (48% vs. 40%).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>HBV remains a substantial contributor to HCC in Australia. Gaps in antiviral treatment and cirrhosis recognition persist, highlighting missed opportunities for prevention and early detection. Interventions to improve linkage to care and delivery of guideline-based HBV management are urgently needed.</p>\u0000 </section>\u0000 </div>","PeriodicalId":15877,"journal":{"name":"Journal of Gastroenterology and Hepatology","volume":"41 10","pages":"3128-3139"},"PeriodicalIF":3.5,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jgh.70680","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148794031","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optimization of Minocycline-Containing Bismuth Quadruple Therapy for Helicobacter pylori Rescue Treatment: A Randomized Controlled Trial","authors":"Yanan Gao,&nbsp;Yu Huang,&nbsp;Jinnan Chen,&nbsp;Shuhan Qiu,&nbsp;Yixian Guo,&nbsp;Meixuan Li,&nbsp;Xiao Liang,&nbsp;Hong Lu","doi":"10.1111/jgh.70677","DOIUrl":"10.1111/jgh.70677","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background and Aim</h3>\u0000 \u0000 <p>Minocycline-containing bismuth quadruple therapy may provide a practical option for <i>Helicobacter pylori</i> (<i>H. pylori</i>) rescue treatment when tetracycline is unavailable, yet the optimal dosing remains unclear. We aimed to compare the efficacy and safety of different doses of minocycline-containing regimens with classical tetracycline-based bismuth quadruple therapy.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Refractory <i>H. pylori</i>–infected participants with multiple treatment-failure were randomly (1:1:1:1) allocated to receive 14-day therapy with vonoprazan 20 mg b.i.d, bismuth 220 mg b.i.d, plus tetracycline 400 mg q.i.d and metronidazole 500 mg q.i.d (BQT), or minocycline 50 mg t.i.d and metronidazole 400 mg t.i.d (VBMn₃M₃), or minocycline 50 mg b.i.d and metronidazole 400 mg q.i.d (VBMn₂M₄), or minocycline 50 mg b.i.d and metronidazole 400 mg t.i.d (VBMn₂M₃). Primary outcome was <i>H. pylori</i> eradication rate evaluated by ¹³C-urea breath test at least 6 weeks after the end of treatment.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Totally, 480 participants were randomized. Eradication rates of BQT, VBMn₃M₃, VBMn₂M₄, and VBMn₂M₃ were 90.0%, 92.5%, 90.8%, and 91.7% by intention-to-treat analysis; 97.3%, 97.4%, 97.3%, and 96.5% by modified intention-to-treat analysis; 98.2%, 97.4%, 97.2%, and 96.4% by per-protocol analysis. There were no statistically significant differences in eradication rates among the regimens, and noninferiority of minocycline-based regimens was confirmed (<i>p</i> &lt; 0.025). Metronidazole resistance did not affect the efficacy. VBMn₂M₃ group achieved the lowest overall incidence of adverse events.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Low-dose minocycline-containing quadruple therapy provided similar eradication rates, adherence, and lower adverse event rates compared with classical bismuth quadruple therapy, and may serve as a practical substitute strategy for <i>H. pylori</i> rescue treatment when tetracycline access is limited.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Trial Registration</h3>\u0000 \u0000 <p>ClinicalTrials.gov: NCT06561711</p>\u0000 </section>\u0000 </div>","PeriodicalId":15877,"journal":{"name":"Journal of Gastroenterology and Hepatology","volume":"41 10","pages":"3109-3117"},"PeriodicalIF":3.5,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148808755","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hepatic Steatosis and Low-Density Lipoprotein Cholesterol Response After Statin Initiation: A Prospective Cohort Analysis","authors":"Kristopher Cho-Hei Lau,&nbsp;Vincent Wai-Sun Wong,&nbsp;Alice Pik-Shan Kong,&nbsp;Grace Lai-Hung Wong,&nbsp;Jimmy Che-To Lai,&nbsp;Winnie Chiu-Wing Chu,&nbsp;Terry Cheuk-Fung Yip","doi":"10.1111/jgh.70656","DOIUrl":"10.1111/jgh.70656","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background and Aims</h3>\u0000 \u0000 <p>Metabolic dysfunction–associated steatotic liver disease (MASLD) is strongly associated with dyslipidemia, which is a major risk factor for cardiovascular diseases and the leading cause of mortality in MASLD. This study aimed to compare the low-density lipoprotein cholesterol (LDL-C) response to statins in patients with and without hepatic steatosis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We identified subjects from a population screening program for MASLD who were subsequently started on statins. Statin response was defined as the absolute decrease between prestatin LDL-C level and LDL-C levels from months 0 to 3 and from months 3 to 12, modelled using multivariable linear mixed models.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Among 922 subjects who underwent proton-magnetic resonance spectroscopy screening, 286 received statin during follow-up, among whom 132 (46%) had hepatic steatosis (liver fat fraction ≥ 5%) at baseline. The mean defined daily dose of statins was 0.50 ± 0.32 units. The analysis on LDL-C average change per month over 12 months revealed no significant association between hepatic steatosis and statin response. Hepatic steatosis showed a nonsignificant association with poorer statin response over months 0–3 (difference of 0.097 mmol/L per month vs. no hepatic steatosis, <i>p</i> = 0.231) and months 3–12 (−0.037 mmol/L per month, <i>p</i> = 0.141), which remained after adjusting for diabetes, BMI, defined daily dose of statin, use of other lipid-lowering drugs, age, and sex.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The association between hepatic steatosis and poorer LDL-C response to statins, if any, is not clinically significant. Patients with hepatic steatosis are recommended to receive a standard statin dose according to clinical indications.</p>\u0000 </section>\u0000 </div>","PeriodicalId":15877,"journal":{"name":"Journal of Gastroenterology and Hepatology","volume":"41 10","pages":"3188-3198"},"PeriodicalIF":3.5,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148689210","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to \"Patient-Level Predictors of Procedural Success in Colon Capsule Endoscopy\".","authors":"Ian Io Lei, Prashanth Vuggumudi, Kiara Mcdonnell, Ramesh P Arasaradnam, Anastasios Koulaouzidis","doi":"10.1111/jgh.70675","DOIUrl":"10.1111/jgh.70675","url":null,"abstract":"","PeriodicalId":15877,"journal":{"name":"Journal of Gastroenterology and Hepatology","volume":" ","pages":"3250-3251"},"PeriodicalIF":3.5,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148759870","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Methodological Considerations in Real-World Evaluation of Durvalumab Plus Tremelimumab for Unresectable Hepatocellular Carcinoma.","authors":"Arienmughare Oghenetega, Amna Ghaffar, Mehnaz Ejaz Khokhar, Chinonye Opene, Emmanuel Edigberhi, Olatunji Emmanuel Fadiora","doi":"10.1111/jgh.70673","DOIUrl":"10.1111/jgh.70673","url":null,"abstract":"","PeriodicalId":15877,"journal":{"name":"Journal of Gastroenterology and Hepatology","volume":" ","pages":"3246-3247"},"PeriodicalIF":3.5,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148765096","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply.","authors":"Anuchit Suksamai, Sakkarin Chirapongsathorn","doi":"10.1111/jgh.70696","DOIUrl":"10.1111/jgh.70696","url":null,"abstract":"","PeriodicalId":15877,"journal":{"name":"Journal of Gastroenterology and Hepatology","volume":" ","pages":"3279-3280"},"PeriodicalIF":3.5,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148829276","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}